{
  "abstract": "BACKGROUND: Modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine is used globally for disease prevention. Real-world safety data following co-administration of MVA-BN with other vaccines is limited.\n\nAIM: To characterise the adverse event profile of MVA-BN given alone or concomitantly with other vaccines using data from Australia’s active vaccine safety surveillance (AusVaxSafety).\n\nMETHODS: Individuals (≥ 18 years) who received MVA-BN between 30 August 2022 and 20 April 2023 at sentinel AusVaxSafety surveillance sites and registered via QR code were surveyed on days 7 and 14 post-vaccination regarding adverse events following immunisation (AEFI), medical review by a healthcare professional and impact on daily activities. Analyses included participants who completed both surveys. Outcomes were compared by administration route, dose and concomitant vaccination status.\n\nRESULTS: Among 10,943 participants (response rate: 46%; 97% male), 200 (1.8%) received at least one concomitant vaccine. Across 14 days, AEFI rates were comparable or lower in concomitant recipients following intradermal administration (alone: 56% (Dose 1), 36% (Dose 2) vs concomitant: 53% (Dose 1), 32% (Dose 2)) and subcutaneous administration (alone: 49% (Dose 1), 32% (Dose 2) vs concomitant: 28% (Dose 1) and 24% (Dose 2)). Medical review was uncommon (0–2.7%). Impact on daily activities was low across groups (6% vs 3.5%), with most symptoms lasting ≤ 1 day.\n\nCONCLUSION: The frequency and severity of AEFIs within 14 days post-vaccination were similar between concomitant and non-concomitant group. These findings provide preliminary, exploratory evidence supporting the safe co-administration of MVA-BN with other adult vaccines, primarily in adult men, and may help inform future immunisation policy and public health recommendations.",
  "abstract_shown": true,
  "affiliations": [
    "National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia",
    "The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Thuy Nguyen",
      "orcid": "0000-0002-0558-8662"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Kristine Macartney",
      "orcid": "0000-0002-4675-0232"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Nicholas Wood",
      "orcid": "0000-0002-3830-5307"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Lucy Dawes",
      "orcid": "0009-0000-2908-7363"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Lucy Deng",
      "orcid": "0000-0003-0066-2218"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fjsarwma4x9bf.bib",
  "cited_by": 0,
  "doi": "10.2807/1560-7917.es.2026.31.44.2600181",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13743899/",
  "id": "fjsarwma4x9bf",
  "issns": [
    "1025-496X",
    "1560-7917"
  ],
  "landing_url": "https://doi.org/10.2807/1560-7917.es.2026.31.44.2600181",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2406|Poxvirus research and outbreaks"
    ]
  ],
  "openalex": "W7225387361",
  "pdf_url": "https://www.eurosurveillance.org/deliver/fulltext/eurosurveillance/31/44/eurosurv-31-44-5.pdf?itemId=%2Fcontent%2F10.2807%2F1560-7917.ES.2026.31.44.2600181&mimeType=pdf&containerItemId=content/eurosurveillance",
  "pmcid": "PMC13743899",
  "pmid": "42990027",
  "published": "2026-11-05",
  "publisher": "European Centre for Disease Prevention and Control",
  "ris": "https://research.draconitic.com/paper/fjsarwma4x9bf.ris",
  "sources": [
    {
      "first_seen": "2026-11-11T12:21:31Z",
      "native_id": "PMC13743899",
      "source": "pmc",
      "url": "https://doi.org/10.2807/1560-7917.es.2026.31.44.2600181"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2406|Poxvirus research and outbreaks",
      "subfield": "microbiology"
    }
  ],
  "title": "Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023",
  "title_text": "Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023",
  "type": "peer-reviewed",
  "updated_at": "2026-11-11T12:21:31Z",
  "url": "https://research.draconitic.com/paper/fjsarwma4x9bf",
  "venue": "Eurosurveillance",
  "versions": []
}